MedTrace Logo

Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

NCT02849548 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.

Conditions

Interventions

DRUG

suvorexant

First in class orexin antagonist approved by the FDA for the treatment of insomnia

OTHER

placebo

Pill with inactive ingredients

Sponsors & Collaborators

  • Georgetown-Howard Universities Center for Clinical and Translational Science

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Howard University

    lead OTHER

Principal Investigators

  • Ihori Kobayashi, Ph.D. · Howard University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-03
Primary Completion
2021-05-17
Completion
2021-05-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849548 on ClinicalTrials.gov